Veracyte Presents First Prospective Validation Data for Hormone Therapy Biomarker in Recurrent Prostate Cancer at ASTRO 2025
核心洞察
Veracyte will present the first prospective validation data for a molecular signature predicting hormone therapy benefit in men with recurrent prostate cancer at ASTRO 2025.
The findings were derived using Veracyte's Decipher GRID research tool, which contains more than 200,000 whole-transcriptome profiles from patients with urologic cancers.
Nine Decipher-focused abstracts, including six podium presentations, will be presented at the conference, examining adverse molecular features in prostate cancer.
Veracyte, Inc. (Nasdaq: VCYT) announced that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men with recurrent prostate cancer will be presented at ASTRO 2025, the annual meeting of the American Society for Radiation Oncology. The findings were derived using Veracyte's Decipher GRID (Genomic Resource for Intelligent Discovery) research tool and represent a significant advancement in precision oncology for prostate cancer treatment.
The study is among nine Decipher-focused abstracts—including six selected for podium presentations—in prostate cancer that will be presented at the conference, being held September 27 to October 1 at the Moscone Center in San Francisco.
Advancing Precision Prostate Cancer Care
"We look forward to the presentation of important new data examining the role of adverse molecular features in predicting disease progression and treatment response for patients with prostate cancer," said Elai Davicioni, Ph.D., Veracyte's medical director for Urology. "Such insights will ultimately make prostate cancer care more precise, giving greater molecular dimension to the classification and treatment of the disease."
Davicioni emphasized the company's unique position in the field, stating, "We believe that our Decipher GRID research tool, combined with our extensive database of prostate tumor whole-transcriptome-derived genomic profiles—the largest of its kind in prostate cancer research—uniquely positions Veracyte to usher in the next generation of cancer diagnostics."
Key Research Presentations
Among the notable presentations examining the role of adverse molecular features in prostate cancer are two significant studies:
The first is a double-blinded placebo-controlled biomarker stratified randomized trial of Apalutamide (APA) and radiotherapy for recurrent prostate cancer (NRG GU006, BALANCE trial), which will be presented by Daniel Spratt, M.D., from University Hospitals Seidman Cancer Center, Case Western Reserve University, as a podium presentation on Sunday, September 28.
The second presentation will examine the discordance of adverse molecular features between the 22-gene genomic classifier score, histologic grade, and NCCN risk groups through analysis of over 200,000 patients. This study will be presented by Michael Zelefsky, M.D., FASTRO, from NYU Langone Laura and Isaac Perlmutter Cancer Center on Wednesday, October 1.
Decipher GRID Database and Technology
The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis.
Clinical Impact of Decipher Prostate Test
The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients across the full spectrum of prostate cancer. The test is performed on biopsy or surgically resected samples and conveys the aggressiveness of the cancer.
For patients with localized or regional prostate cancer, the Decipher score indicates a patient's risk of metastasis, helping to determine treatment timing and intensity. For patients with metastatic prostate cancer, the Decipher score indicates the likelihood of cancer progression and survival benefit with treatment intensification.
The Decipher Prostate test's performance and clinical utility has been demonstrated in over 90 studies involving more than 200,000 patients. It is the only gene expression test to achieve "Level I" evidence status and inclusion in the risk-stratification table in the most recent NCCN Guidelines for prostate cancer.